Get to know our clinical trials
Phase I clinical trial of IMC-P115C in participants with PRAME-positive advanced cancers.
THE MAIN OBJECTIVE IS TO EVALUATE THE SAFETY AND TOLERABILITY OF IMC-P115C AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH PRAME-POSITIVE ADVANCED TUMORS, AND TO IDENTIFY THE MTD (MAXIMUM TOLERATED DOSE) AND DOSING REGIMENS (COMBINATION OF IMC-P115C DOSE, DOSING FREQUENCY, AND PREMEDICATION) FOR FURTHER OPTIMIZATION.
Technical Summary
- FIRST-IN-HUMAN PHASE I STUDY ON THE SAFETY AND EFFICACY OF IMC-P115C AS MONOTHERAPY AND IN COMBINATION WITH STANDARD-OF-CARE AGENTS IN HLA-A*02:01-POSITIVE PARTICIPANTS WITH PRAME-POSITIVE ADVANCED CANCERS.
- Code EudraCT: 2023-509767-25
- Protocol number: IMC-P115C-1005
- Promoter: Immunocore Ltd.
- Molecule/Drug: IMC-P115C
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.